Progress of Researches on Prediction of Tyrosine Kinase Inhibitor Efficacy for Treatment of Chronic Myelocid Leukemia -Review.
10.7534/j.issn.1009-2137.2017.01.045
- Author:
Yi-Han DING
1
;
Yu-Feng LI
2
Author Information
1. Department of Hematology, Huai'an First People's Hospital of Nanjing Medical University, Huaian 223300, Jiangsu Province, China.
2. Department of Hematology, Huai'an First People's Hospital of Nanjing Medical University, Huaian 223300, Jiangsu Province, China. E-mail: liyufeng99@netease.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2017;25(1):249-254
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitors (TKI) have made a dramatic improvement in the clinical efficacy of chronic myelogenous leukemia, but the occurrence of TKL resistance and intolerance does not enable some patients to acquire the satisfactory efficacy. Screening the proper TKL for patients with high risk before the treatment and conversing drug timely based on early detection of TKL resistance are helpful to accurately use TKI and enhance therapeutic efficacy. In this article, the function of some indicators, such as baseline clinical, biochemical and molecular biological characteristics and influence of early treatment response law of imatinib on long-term prognosis of newly diagnosed patients are summarized.
